Novartis AG (LTS:0QM7) Research & Development: CHF9,239.11 Mil (TTM As of Mar. 2026)


What is Novartis AG Research & Development?

Novartis AG LTS:0QM7 83 Research & Development is CHF9,239.11 Mil as of Mar. 2026. GuruFocus rates LTS:0QM7 with a GF Score™ of 83/100. The stock has 7 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Novartis AG's Research & Development for the three months ended in Mar. 2026 was CHF2,157.20 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was CHF9,239.11 Mil.

Novartis AG  (LTS:0QM7) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Novartis AG Research & Development Related Terms

Novartis AG Research & Development Historical Data

* Premium members only.

The historical data trend for Novartis AG's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novartis AG Research & Development Chart

Novartis AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7,958.36 8,544.64 9,833.64 8,935.62 8,925.28

Novartis AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,090.60 2,217.60 2,343.72 2,520.60 2,157.20

Novartis AG Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF9,239.11 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of CHF9,239.11 Mil mean?
Novartis AG (LTS:0QM7) has a Research & Development of CHF9,239.11 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Novartis AG and its competitors.
Is Novartis AG's Research & Development too high?
Novartis AG's current Research & Development is CHF9,239.11 Mil. Overall, Novartis AG has a GF Score™ of 83/100, reflecting its overall financial health beyond just this single metric.
How does Novartis AG's Research & Development compare to LLY and JNJ?
Novartis AG's Research & Development of CHF9,239.11 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Novartis AG and its competitors. Novartis AG's current Research & Development is CHF9,239.11 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novartis AG stock overvalued right now?
Novartis AG (LTS:0QM7) has a current Research & Development of CHF9,239.11 Mil. The current Research & Development is CHF9,239.11 Mil. Novartis AG's overall GF Score™ is 83/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Novartis AG (LTS:0QM7), the current Research & Development is CHF9,239.11 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Novartis AG Business Description

Address Lichtstrasse 35, Basel, CHE, 4056
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.